Pipeline
PRINT Technology
About Liquidia
Newsroom
Investors
Contact Us
Careers

About Liquidia
PRINT Technology
Pipeline
Investors
Newsroom
Careers
Contact Us

Investors

Jefferies Virtual Healthcare Conference

Jefferies Virtual Healthcare Conference

Jun 2, 2020 at 10:30 AM EDT

Click here for webcast

Overview
Press Releases
Events & Presentations
Stock Information
Proxy Online
Corporate Governance
SEC Filings
Investor Resources
Email Alerts

52 Week High

52 Week Low

Volume

Feb 12, 2021 10:10 PM EST

Tools

Email Alerts

Email Alerts
RSS

RSS
Print

Print
Email Page

Email Page

Home
About Liquidia
— Leadership
— Board of Directors
— Collaborations
— Business Development

PRINT Technology
— Publications

Pipeline
— LIQ861
— LIQ865

Investors

Newsroom
— Media Contact

Contact
— General Inquiries
— Map/Directions

Careers
— Career Opportunities
— Life at Liquidia
— Benefits

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain.

PO Box 110085, Research Triangle Park, NC 27709

Tel +1 919-328-4400

Fax +1 919-328-4402

Liquidia

© 2018 Liquidia Technologies

Legal Privacy Cookies Social Media